Emergent Biosolutions (NYSE:EBS) EVP Sells $306,080.00 in Stock

Emergent Biosolutions Inc. (NYSE:EBS) EVP Coleen Glessner sold 30,608 shares of the stock in a transaction that occurred on Tuesday, October 7th. The shares were sold at an average price of $10.00, for a total transaction of $306,080.00. Following the transaction, the executive vice president owned 144,319 shares in the company, valued at approximately $1,443,190. This trade represents a 17.50% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Emergent Biosolutions Stock Down 2.9%

Shares of EBS stock opened at $9.13 on Friday. Emergent Biosolutions Inc. has a 12 month low of $4.02 and a 12 month high of $12.73. The stock has a market cap of $487.09 million, a P/E ratio of 3.73 and a beta of 2.04. The company has a current ratio of 5.66, a quick ratio of 3.00 and a debt-to-equity ratio of 1.25. The company has a 50 day simple moving average of $8.68 and a two-hundred day simple moving average of $6.99.

Emergent Biosolutions (NYSE:EBS) last announced its earnings results on Tuesday, January 9th. The biopharmaceutical company reported ($1.27) EPS for the quarter. Emergent Biosolutions had a net margin of 16.38% and a return on equity of 24.63%. The business had revenue of $222.50 million for the quarter. Emergent Biosolutions has set its FY 2023 guidance at EPS. On average, research analysts expect that Emergent Biosolutions Inc. will post -0.63 earnings per share for the current year.

Analyst Upgrades and Downgrades

EBS has been the subject of a number of research reports. HC Wainwright reaffirmed a “buy” rating and set a $15.00 target price on shares of Emergent Biosolutions in a report on Wednesday, September 3rd. Weiss Ratings reissued a “sell (d)” rating on shares of Emergent Biosolutions in a research note on Wednesday, October 8th. Finally, Wall Street Zen cut shares of Emergent Biosolutions from a “buy” rating to a “hold” rating in a research note on Saturday, August 9th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $13.50.

Institutional Trading of Emergent Biosolutions

A number of hedge funds and other institutional investors have recently modified their holdings of EBS. Legal & General Group Plc purchased a new stake in shares of Emergent Biosolutions in the second quarter worth $31,000. Ameritas Investment Partners Inc. bought a new stake in Emergent Biosolutions in the 2nd quarter valued at $35,000. Raymond James Financial Inc. bought a new stake in Emergent Biosolutions in the 2nd quarter valued at $53,000. SBI Securities Co. Ltd. increased its holdings in Emergent Biosolutions by 95.1% in the 1st quarter. SBI Securities Co. Ltd. now owns 12,951 shares of the biopharmaceutical company’s stock valued at $63,000 after acquiring an additional 6,313 shares during the last quarter. Finally, Janney Montgomery Scott LLC bought a new stake in Emergent Biosolutions in the 2nd quarter valued at $68,000. 78.40% of the stock is owned by hedge funds and other institutional investors.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.